Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Diabetes mellitus I“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Diabetes mellitus I" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Diabetes mellitus I"
Doamekpor, Caleb. „Diabetes Mellitus“. Acta Scientific Pharmaceutical Sciences 4, Nr. 2 (31.01.2020): 01–09. http://dx.doi.org/10.31080/asps.2020.04.diabetes-mellitus.
Der volle Inhalt der QuelleGÜRBÜZ, Murat, und Menşure Nur ÇELİK. „Minerals and Diabetes Mellitus“. Turkiye Klinikleri Journal of Internal Medicine 4, Nr. 2 (2019): 71–83. http://dx.doi.org/10.5336/intermed.2018-64388.
Der volle Inhalt der QuelleChaudhary, Nitin, und Nidhi Tyagi. „Diabetes mellitus: An Overview“. International Journal of Research and Development in Pharmacy & Life Sciences 7, Nr. 4 (August 2018): 3030–33. http://dx.doi.org/10.21276/ijrdpl.2278-0238.2018.7(4).3030-3033.
Der volle Inhalt der QuelleAmbulkar, Sunil, Parimal Tayde, Makarand Randive und Mukund Ganeriwal. „Diabetes mellitus in pregnancy“. New Indian Journal of OBGYN 4, Nr. 1 (Juli 2017): 4–9. http://dx.doi.org/10.21276/obgyn.2017.4.1.2.
Der volle Inhalt der QuelleBegum, SA, R. Afroz, Q. Khanam, A. Khanom und TS Choudhury. „Diabetes Mellitus and Gestational Diabetes Mellitus“. Journal of Paediatric Surgeons of Bangladesh 5, Nr. 1 (30.06.2015): 30–35. http://dx.doi.org/10.3329/jpsb.v5i1.23887.
Der volle Inhalt der QuelleDaidano, Jeando Khan, Nazia Azam Yusfani und Bilqees Daidano. „DIABETES MELLITUS“. Professional Medical Journal 25, Nr. 06 (09.06.2018): 881–86. http://dx.doi.org/10.29309/tpmj/18.4535.
Der volle Inhalt der QuellePelikánová, Terezie. „Diabetes mellitus and cardiovascular diseases“. Cor et Vasa 53, Nr. 4-5 (01.04.2011): 242–48. http://dx.doi.org/10.33678/cor.2011.054.
Der volle Inhalt der QuelleGoldmannová Ondřej Krystyník David Karásek, Dominika, und Josef Zadražil. „Diabetes mellitus after organ transplantation“. Interní medicína pro praxi 21, Nr. 1 (21.02.2019): 20–23. http://dx.doi.org/10.36290/int.2019.003.
Der volle Inhalt der QuellePoskerová, H., P. Linhartová, J. Vokurka, A. Fassmann und L. Hollá. „Diabetes Mellitus and Oral Health“. Česká stomatologie/Praktické zubní lékařství 114, Nr. 5 (01.12.2014): 75–86. http://dx.doi.org/10.51479/cspzl.2014.018.
Der volle Inhalt der QuellePadmasri Devi, P., M. Mahalakshmi, V. Sarojini Devi, M. Kiran Deedi, Ch Ganapathi Swamy und V. Thoyoja Durga. „Prevalence of Gestational Diabetes Mellitus“. Indian Journal of Obstetrics and Gynecology 7, Nr. 2 (2019): 309–11. http://dx.doi.org/10.21088/ijog.2321.1636.7219.31.
Der volle Inhalt der QuelleDissertationen zum Thema "Diabetes mellitus I"
Grou, Isabel Maria Lampreia. „Diabetes mellitus em canídeos“. Bachelor's thesis, Universidade Técnica de Lisboa. Faculdade de Medicina Veterinária, 2008. http://hdl.handle.net/10400.5/900.
Der volle Inhalt der QuelleA diabetes mellitus é uma insuficiência absoluta ou relativa de insulina que resulta da deficiente secreção desta por parte das células pancreáticas ou da oposição à acção da insulina. A diabetes é uma das endocrinopatias mais frequentes no cão. Quando é diagnosticado com diabetes mellitus, o animal pode encontrar-se num estado dependente de administração exógena de insulina de insulina, em que as células já não produzem insulina, ou num estado de não dependente de insulina, em que as células ainda possuem alguma função residual. No cão, a diabetes mellitus dependente de insulina é uma patologia multifactorial. Alguns dos factores implicados na etiologia da doença são: predisposição genética, infecção, patologia que provoque antagonismo à insulina, fármacos, obesidade, insulite imunomediada e pancreatite. Todos os factores referidos desempenham um papel que culmina na perda de função das células , hipoinsulinemia, deficiência no transporte da glucose para o interior das células e aceleração do processo de gluconeogénese hepática e glicogenólise. A insuficiência em insulina provoca a diminuição da utilização da glucose, levando a hiperglicemia. A glucose, como é uma molécula pequena, é filtrada pelo glomérulo renal; quando a capacidade de reabsorção de glucose das células dos túbulos renais a partir do filtrado glomerular é excedida, ocorre glicosúria. A glicosúria provoca diurese osmótica, que leva a polidipsia. Como a entrada da glucose nas células do centro da saciedade é mediada pela insulina, o centro da saciedade não inibe o centro da alimentação. Os quatro sinais clássicos de diabetes são então poliúria, polidipsia, polifagia e perda de peso. O principal objectivo da terapêutica instituída é eliminar os sinais clínicos observados pelo dono, o que pode ser conseguido com uma administração ponderada de insulina, dieta, exercício e com a prevenção ou controlo de doenças inflamatórias, infecciosas, neoplásicas e endócrinas. As complicações mais frequentes são cegueira devido à formação de cataratas, pancreatite crónica e infecções recorrentes do tracto urinário, das vias respiratórias e da pele. Os animais diabéticos têm ainda o risco de desenvolver hipoglicemia e cetoacidose. A cetoacidose diabética é consequência da diabetes que resulta em formação de corpos cetónicos no fígado, em acidose metabólica, desidratação severa, choque e possivelmente morte. A maior parte dos cães diabéticos vive menos de 5 anos após o diagnóstico, sendo que os primeiros seis meses são decisivos para o controlo da doença. Com cuidados apropriados por parte dos donos, avaliações regulares por parte do veterinário e uma boa comunicação entre o cliente e o médico veterinário, muitos animais diabéticos podem levar vidas relativamente normais durante vários anos.
ABSTRACT - Diabetes mellitus, which is a very common endocrinopathy in the dog, is an absolute or relative insufficiency in the production of insulin by the pancreatic cells or an impaired sensitivity to the hormone or both. When diagnosed with diabetes mellitus some animal may need insulin therapy immediately, for their cells produce no insulin - insulin dependent diabetes mellitus, and some others may have a slower loss of function of cells - non-insulin dependent diabetes mellitus. The etiology of insulin dependent diabetes mellitus in the dog is multifactorial, being related to genetic susceptibility, infections, insulin resistance inducing disease, drugs, obesity, immune mediated insulitis and pancreatitis. All these factors lead to the functional loss of pancreatic cells, impaired transport of glucose into cells and enhancing the hepatic gluconeogenesis and glycogenolisis. The classic clinical signs of diabetes mellitus are polyuria, polydipsia, polyphagia and weight loss. The insulin deficiency leads to a decrease in glucose use and sequent hyperglycemia. Being a small molecule, glucose is filtrated in the renal glomérulos; when the ability of reabsorbing glucose of the tubular cells is overwhelmed, glycosuria occurs. Glycosuria leads to osmotic diuresis, which in turn leads to polydipsia. To enter the satiety center cells, glucose needs insulin. Without it, the satiety center never inhibits the hunger center. The treatment of diabetes aims to control the clinical signs described, and that con be achieved with insulin therapy, diet, exercise and prophylaxis and control of infectious, inflammatory, neoplastic or endocrine diseases. The most frequent consequences of diabetes mellitus in dogs are blindness as a consequence of diabetic cataracts, chronic pancreatitis and urinary tract, skin and upper respiratory tract infections. Diabetic dogs have an increased risk of developing hypoglycemia and ketoacidosis. Ketoacidosis leads to hepatic production of ketone bodies, metabolic acidosis, severe dehydration and even death. Most diabetic dogs live up to 5 years after they are diagnosed, the six first months being the most important ones. With proper care from the owner, regular reevaluations with the veterinarian and good communication between veterinarian and owner, the diabetic dog can have an ordinary life for several years.
Nordwall, Maria. „Long term complications in juvenile diabetes mellitus“. Doctoral thesis, Linköping : Univ, 2006. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-6377.
Der volle Inhalt der QuelleBeales, Philip Edward. „Diabetes prevention in the non-obese diabetic mouse“. Thesis, University of East London, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.265059.
Der volle Inhalt der QuelleClifford, Rhonda Marise. „Pharmaceutical care in diabetes mellitus“. Curtin University of Technology, School of Pharmacy, 2004. http://espace.library.curtin.edu.au:80/R/?func=dbin-jump-full&object_id=14951.
Der volle Inhalt der QuelleDemographic parameters, including ethnicity and treatment details, were reviewed at study entry for the full FDS cohort and then over time for a subset of patients that returned for four subsequent annual assessments. Insulin use was more common in patients of Southern European origin compared with the Anglo-Celt group irrespective of the level of glycaemia, at baseline. This difference persisted during subsequent follow-up but was not associated with improved glycaemic control. These findings demonstrated that there are important ethnic differences in the management of patients with type 2 diabetes mellitus. The pilot pharmaceutical care program was carried out in high-risk diabetes mellitus patients attending a hospital outpatient clinic. The patients had poor glycaemic control, dyslipidaemia, hypertension and/or were on three or more prescription medications. In the pharmaceutical care arm, a clinical pharmacist reviewed and monitored all aspects of the patients' drug therapy in collaboration with other health care professionals at six weekly intervals for six months. The control patients received usual outpatient care. Seventy-three patients were recruited into the study, of whom 48 (66%) were randomised to receive pharmaceutical care. One in six patients was taking complementary medicines. The pharmaceutical care program provided patients with important medication information that resulted in changes to drug therapy. However, the six-month program did not lead to an improvement in glycaemic control. The next phase of the study adapted the pilot hospital-based pharmaceutical care program to a community-based setting.
Two hundred and two type 2 diabetes mellitus FDS patients were recruited, of whom 101 (50%) were randomised to the pharmaceutical care program, and all were followed for 12-months. There were significant reductions in risk factors associated with coronary heart disease in the case but not the control group over time, specifically glycaemic control, lipid levels, and blood pressure. Glycosylated haemoglobin fell from 7.5% to 7.0% (P<0.0001), total cholesterol fell from 5 mmol/L to 4.6 mmol/L (P<0.0001), systolic blood pressure fell from 158 mmHg to 143 mmHg (P<0.0001) and diastolic blood pressure fell from 77mmHg to 71mmHg (P<0.0001). Multiple linear regression analysis confirmed that pharmaceutical care program involvement was an independent predictor of benefit after adjustment for key variables. The 10-year coronary heart disease risk for patients without a previous coronary event was reduced by 4.6% over the 12-month study period in the pharmaceutical care group (P<0.0001), while there was no change in the controls (P=0.23). This phase of the study showed that medium-term individualised pharmaceutical care reduced vascular risk factors in a community-based cohort of patients with diabetes and that provision of a multifactorial intervention can improve health outcomes in type 2 diabetes mellitus. As part of the pharmaceutical care program, a high level of complementary medicine use was found. As a result, a study of complementary medicine use was undertaken in 351 patients from the FDS. A convenience sample of FDS patients was interviewed regarding their use of complementary medicines. A literature search was conducted to assess the potential impact of these medicines on diabetes, concomitant medications or diabetes-related co-morbidities.
Eighty-three of 351 (23.6%) patients with diabetes had consumed at least one complementary medicine in the previous year and 42% (77/183) of the products potentially necessitated additional patient monitoring or could be considered potentially inappropriate for a diabetic patient. The data indicated the need for patient disclosure of complementary medicine use and adequate monitoring for complementary medicine-related adverse events, as part of the pharmaceutical care process. The pharmaceutical care model was established to provide a framework by which drug use could be improved to enhance patients' clinical and health-related quality of life outcomes. For the present study, a straightforward pharmaceutical care program was adapted from a hospital setting to a community setting, where the principal requirement was a clinical pharmacist who had completed a self-directed diabetes-training program. In this context, clinically relevant parameters improved over the course of the study period. Pharmaceutical care programs such as this can begin the process of translating the findings of large and expensive clinical trials into standard clinical practice.
Sels, Jean-Pierre Joseph Emile. „Dietary fibre and diabetes mellitus“. Maastricht : Maastricht : Datawyse ; University Library, Maastricht University [Host], 1991. http://arno.unimaas.nl/show.cgi?fid=5618.
Der volle Inhalt der QuelleChan, Juliana Chung Ngor. „Diabetes mellitus in Hong Kong“. Thesis, University of Liverpool, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246160.
Der volle Inhalt der QuelleTalwar, D. „Glucosylated haemoglobin and diabetes mellitus“. Thesis, University of Strathclyde, 1985. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.371982.
Der volle Inhalt der QuelleLutgers, Helen Lucia. „Skin autofluorescence in diabetes mellitus“. [S.l. : [Groningen : s.n.] ; University Library Groningen] [Host], 2008. http://irs.ub.rug.nl/ppn/.
Der volle Inhalt der QuellePinto, Mariana de Carvalho [UNESP]. „Parâmetros Neuropáticos no Diabetes Mellitus“. Universidade Estadual Paulista (UNESP), 2014. http://hdl.handle.net/11449/123212.
Der volle Inhalt der QuelleA neuropatia diabética é caracterizada por uma síndrome clínica ou sub -clínica que afeta o sistema nervoso central e periférico, incluindo o autonômico. Frente ao crescente número de novos casos de diabetes mellitus e a elevada incidência de manifestações crônico - degenerativas, como a neuropatia periférica e a neuropatia autonômica cardiovascular, este estudo objetivou: a) fazer uma comparação da variabilidade cardíaca (VC), em indivíduos com diabetes mellitus tipo 2 com confirmação de neuropatia diabética periférica, e indivíduos saudáveis.; b) identificar o risco de queda através de um teste de mobilidade fun cional em não diabéticos, diabéticos neuropatas e diabéticos neuropata -vasculopatas. Para tanto, no primeiro estudo participaram 108 indivíduos divididos em grupo controle (GC) (n=34) e grupo diabético neuropata (GDN) (n=74). Inicialmente, foram reali zados testes para confirmação da neuropatia. Em seguida, a avaliação da atividade do sistema nervoso autônomo (SNA) foi realizada por meio da VC com o auxílio do software Nerve -Express® (Heart Rhythm Instruments, Metuchen, NJ, EUA). Já o segundo estudo, foi composto por 61 sujeitos de ambos os gêneros divididos em GC (n=32), GDN (n=18) e grupo diabético neuropata vasculopata (GDNV) (12)...
Diabetic neuropathy is characterized by clinical or sub -clinical syndrome that affects the central and peripheral nervous system including the autonomic. Tackle the growing number of 17 new cases of diabetes mellitus and the high incidence of chronic degenerative disorders, such as peripheral neuropathy and cardiovascular autonomic neuropathy, this study aimed to: a) make a comparison of heart rate variability (CV), in individuals with diabetes mellitus type 2 with confirmation of diabetic peripheral neuropathy, and healthy individuals .; b) identify the risk of falling through a functional mobility test in non -diabetic, diabetic neuropathy and diabetic neuropathy-vasculopathies. Therefore, in the first s tudy participated 108 individuals divided into a control group (CG) (n = 34) and diabetic neuropathy group (GDN) (n = 74). Initially, to confirm the neuropathy tests were performed. Then, the evaluation of the activity of the autonomic nervous system (ANS) was performed by the VC with the help of Nerve - Express® software (Heart Rhythm Instruments, Metuchen, NJ, USA). The second study consisted of 61 subjects of both genders divided into GC (n = 32), GDN (n = 18) and diabetic neuropathy vasculopata group (GDNV) (12)...
Pinto, Mariana de Carvalho. „Parâmetros Neuropáticos no Diabetes Mellitus /“. Presidente Prudente, 2014. http://hdl.handle.net/11449/123212.
Der volle Inhalt der QuelleBanca: Roselene Modolo Regueiro Lorençoni
Banca: Marli Aparecida Defani
Resumo: A neuropatia diabética é caracterizada por uma síndrome clínica ou sub -clínica que afeta o sistema nervoso central e periférico, incluindo o autonômico. Frente ao crescente número de novos casos de diabetes mellitus e a elevada incidência de manifestações crônico - degenerativas, como a neuropatia periférica e a neuropatia autonômica cardiovascular, este estudo objetivou: a) fazer uma comparação da variabilidade cardíaca (VC), em indivíduos com diabetes mellitus tipo 2 com confirmação de neuropatia diabética periférica, e indivíduos saudáveis.; b) identificar o risco de queda através de um teste de mobilidade fun cional em não diabéticos, diabéticos neuropatas e diabéticos neuropata -vasculopatas. Para tanto, no primeiro estudo participaram 108 indivíduos divididos em grupo controle (GC) (n=34) e grupo diabético neuropata (GDN) (n=74). Inicialmente, foram reali zados testes para confirmação da neuropatia. Em seguida, a avaliação da atividade do sistema nervoso autônomo (SNA) foi realizada por meio da VC com o auxílio do software Nerve -Express® (Heart Rhythm Instruments, Metuchen, NJ, EUA). Já o segundo estudo, foi composto por 61 sujeitos de ambos os gêneros divididos em GC (n=32), GDN (n=18) e grupo diabético neuropata vasculopata (GDNV) (12)...
Abstract: Diabetic neuropathy is characterized by clinical or sub -clinical syndrome that affects the central and peripheral nervous system including the autonomic. Tackle the growing number of 17 new cases of diabetes mellitus and the high incidence of chronic degenerative disorders, such as peripheral neuropathy and cardiovascular autonomic neuropathy, this study aimed to: a) make a comparison of heart rate variability (CV), in individuals with diabetes mellitus type 2 with confirmation of diabetic peripheral neuropathy, and healthy individuals .; b) identify the risk of falling through a functional mobility test in non -diabetic, diabetic neuropathy and diabetic neuropathy-vasculopathies. Therefore, in the first s tudy participated 108 individuals divided into a control group (CG) (n = 34) and diabetic neuropathy group (GDN) (n = 74). Initially, to confirm the neuropathy tests were performed. Then, the evaluation of the activity of the autonomic nervous system (ANS) was performed by the VC with the help of Nerve - Express® software (Heart Rhythm Instruments, Metuchen, NJ, USA). The second study consisted of 61 subjects of both genders divided into GC (n = 32), GDN (n = 18) and diabetic neuropathy vasculopata group (GDNV) (12)...
Mestre
Bücher zum Thema "Diabetes mellitus I"
Liao, Tien Ren. Diabetes mellitus. Washington, D.C: Science Reference Section, Science and Technology Division, Library of Congress, 1986.
Den vollen Inhalt der Quelle findenDiabetes mellitus. 2. Aufl. Oxford: Blackwell Scientific, 1986.
Den vollen Inhalt der Quelle findenLiao, Tien Ren. Diabetes mellitus. Washington, D.C: Science Reference Section, Science and Technology Division, Library of Congress, 1986.
Den vollen Inhalt der Quelle findenAmerican College of Obstetricians and Gynecologists, Hrsg. Diabetes mellitus. Seattle, Washington: American College of Obstetricians and Gynecologists, 2013.
Den vollen Inhalt der Quelle findenKishore, P. Diabetes mellitus. Barking: Directorate of Public Health, Barking & Havering Health Authority, 1997.
Den vollen Inhalt der Quelle findenDempsey, Denise P. Diabetes Mellitus. Washington, D.C: Science Reference Section, Science and Technology Division, Library of Congress, 2001.
Den vollen Inhalt der Quelle findenBibergeil, Horst, Hrsg. Diabetes mellitus. Vienna: Springer Vienna, 1989. http://dx.doi.org/10.1007/978-3-7091-7562-0.
Der volle Inhalt der QuelleBretzel, Reinhard G., Hrsg. Diabetes mellitus. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74610-9.
Der volle Inhalt der QuelleKooy, Adriaan. Diabetes mellitus. Houten: Bohn Stafleu van Loghum, 2008. http://dx.doi.org/10.1007/978-90-313-6626-2.
Der volle Inhalt der QuelleNakabeppu, Yusaku, und Toshiharu Ninomiya, Hrsg. Diabetes Mellitus. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-3540-2.
Der volle Inhalt der QuelleBuchteile zum Thema "Diabetes mellitus I"
Hahn, H. J. „Tierexperimenteller Diabetes“. In Diabetes mellitus, 108–17. Vienna: Springer Vienna, 1989. http://dx.doi.org/10.1007/978-3-7091-7562-0_4.
Der volle Inhalt der QuelleMilly, Manuela. „Diabetes mellitus“. In Heimhilfe, 213–18. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-46106-8_22.
Der volle Inhalt der QuelleDemakis, George J. „Diabetes Mellitus“. In Encyclopedia of Clinical Neuropsychology, 1131–34. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-57111-9_550.
Der volle Inhalt der QuellePiper, Brenda. „Diabetes mellitus“. In Diet and Nutrition, 281–86. Boston, MA: Springer US, 1996. http://dx.doi.org/10.1007/978-1-4899-7244-6_17.
Der volle Inhalt der QuelleRosak, C., T. Dunzendorfer und U. Hofmann. „Diabetes mellitus“. In Klinische Pharmakologie, 337–59. Heidelberg: Steinkopff, 2001. http://dx.doi.org/10.1007/978-3-642-57636-2_26.
Der volle Inhalt der QuelleShillitoe, Richard. „Diabetes mellitus“. In Health Psychology, 187–204. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-3226-6_11.
Der volle Inhalt der QuelleShillitoe, Richard W., und David W. Miles. „Diabetes mellitus“. In Health Psychology, 208–33. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4899-3228-0_11.
Der volle Inhalt der QuellePeseschkian, Nossrat. „Diabetes mellitus“. In Psychosomatik und positive Psychotherapie, 203–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-97847-0_16.
Der volle Inhalt der QuelleRosak, C., T. Dunzendorfer und U. Hofmann. „Diabetes mellitus“. In Klinische Pharmakologie, 608–50. Heidelberg: Steinkopff, 1996. http://dx.doi.org/10.1007/978-3-642-97796-1_35.
Der volle Inhalt der QuelleLaycock, John, und Karim Meeran. „Diabetes Mellitus“. In Integrated Endocrinology, 325–36. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118450642.ch15.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Diabetes mellitus I"
Ammutammima, Ummu Fatihah, Didik Gunawan Tamtomo und Bhisma Murti. „Family History with Diabetes Mellitus and the Gestational Diabetes Mellitus: Meta-Analysis“. In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.05.54.
Der volle Inhalt der QuelleSitorukmi, Galuh, Bhisma Murti und Yulia Lanti Retno Dewi. „Effect of Family History with Diabetes Mellitus on the Risk of Gestational Diabetes Mellitus: A Meta-Analysis“. In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.05.55.
Der volle Inhalt der QuelleAlava, I., L. J. Garcia Frade, H. de la Calle, J. L. Havarro, L. J. Creighton und P. J. Gaffney. „DIABETES MELLITUS: HYPERCOAGULABILITY AID HYPOFIBRIHOLYSIS“. In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643108.
Der volle Inhalt der QuelleElcin, Huseyn. „EARLY IDENTIFICATION OF THE NEUROLOGICAL COMPLICATIONS OF DIABETES MELLITUS“. In International Trends in Science and Technology. RS Global Sp. z O.O., 2021. http://dx.doi.org/10.31435/rsglobal_conf/30032021/7474.
Der volle Inhalt der QuelleVasil'ceva, O. YA, und K. N. Vitt. „Diabetes mellitus and thrombotic complications“. In Scientific dialogue: Medical issues. ЦНК МОАН, 2019. http://dx.doi.org/10.18411/spc-15-05-2019-07.
Der volle Inhalt der QuelleEppstein, Jonathan A., und Sven-Erik Bursell. „Noninvasive detection of diabetes mellitus“. In OE/LASE '92, herausgegeben von Thomas S. Mang. SPIE, 1992. http://dx.doi.org/10.1117/12.59364.
Der volle Inhalt der QuelleAprilia, Dinda, Eva Decroli, Alexander Kam, Afdol Rahmadi, Asman Manaf und Syafril Syahbuddin. „Sepsis in Type 1 Diabetes Mellitus with Diabetic Ketoacidosis“. In The 2nd International Conference on Tropical Medicine and Infectious Disease. SCITEPRESS - Science and Technology Publications, 2019. http://dx.doi.org/10.5220/0009859200720074.
Der volle Inhalt der QuelleNugroho, Trilaksana, Hari Peni Julianti, Arief Wildan, rnila Novitasari Saubig, Andhika Guna Darma und Desti Putri Seyorini. „Risk Factor of Dry Eyes Syndrome Toward Elderly with Diabetes Mellitus“. In The 7th International Conference on Public Health 2020. Masters Program in Public Health, Universitas Sebelas Maret, 2020. http://dx.doi.org/10.26911/the7thicph.05.26.
Der volle Inhalt der QuelleKrishnan, Devi R., Chakravarthy Maddipati, Gayathri P. Menakath, Anagha Radhakrishnan, Yarrangangu Himavarshini, Aparna A., Kaveri Mukundan, Rahul Krishnan Pathinarupothi, Bithin Alangot und Sirisha Mahankali. „Evaluation of predisposing factors of Diabetes Mellitus post Gestational Diabetes Mellitus using Machine Learning Techniques“. In 2019 IEEE Student Conference on Research and Development (SCOReD). IEEE, 2019. http://dx.doi.org/10.1109/scored.2019.8896323.
Der volle Inhalt der QuelleBurda, Vaclav, und Daniel Novak. „Mobiab system for diabetes mellitus compensation“. In 2015 International Workshop on Computational Intelligence for Multimedia Understanding (IWCIM). IEEE, 2015. http://dx.doi.org/10.1109/iwcim.2015.7347078.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Diabetes mellitus I"
Pillay, Jennifer, Pritam Chordiya, Sanjaya Dhakal, Ben Vandermeer, Lisa Hartling, Marni J. Armstrong, Sonia Butalia et al. Behavioral Programs for Diabetes Mellitus. Agency for Healthcare Research and Quality, September 2015. http://dx.doi.org/10.23970/ahrqepcerta221.
Der volle Inhalt der QuelleLarcom, Barbara, Rosemarie Ramos, Lisa Lott, J. M. McDonald, Mark True, Michele Tavish, Heidi Beason, Lee Ann Zarzabel, James Watt und Debra Niemeyer. Genetic Risk Conferred from Single Nucleotide Polymorphisms Towards Type II Diabetes Mellitus. Fort Belvoir, VA: Defense Technical Information Center, Februar 2013. http://dx.doi.org/10.21236/ada573655.
Der volle Inhalt der QuelleLI, Wenhui, Xiaoming HU, xuhong WANG, Lei XU, Guobin LIU und Weijing FAN. Telemedicine for blood glucose in Diabetes Mellitus: an Overview of Systematic Reviews. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juni 2021. http://dx.doi.org/10.37766/inplasy2021.6.0024.
Der volle Inhalt der QuelleCui, Sufen. Acupuncture for chronic constipation in patients with diabetes mellitus: a systematic review protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Januar 2021. http://dx.doi.org/10.37766/inplasy2021.1.0079.
Der volle Inhalt der QuelleMermeklieva, Elena. Comparative Analysis of Pattern Electroretinography Values According to the Type of Diabetes Mellitus in Patients in Different Diabetic Retinopathy Stages. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, Mai 2021. http://dx.doi.org/10.7546/crabs.2021.05.18.
Der volle Inhalt der QuelleZhu, Jing, Xiaohong Jiang, Kaiming Luo, Xiaolin Huang und Fei Hua. Association between Lipocalin-2 levels and Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0097.
Der volle Inhalt der QuelleMermeklieva, Elena, Silvia Cherninkova, Violeta Chernodrinska, Dimitar Solakov, Greta Grozeva, Maria Tomova und Ljudmila Todorova. Combined Electrophysiological Method for Early Diagnostics of Functional Changes in the Visual Analyzer in Patients with Diabetes Mellitus withоut Diabetic Retinopathy. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, Mai 2019. http://dx.doi.org/10.7546/crabs.2019.05.16.
Der volle Inhalt der QuelleColonetti, Tamy, Micheli Mariot, Laura Colonetti und Marina Costa. Effects of gluten free diet in patients with diabetes mellitus type1: systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juni 2020. http://dx.doi.org/10.37766/inplasy2020.6.0010.
Der volle Inhalt der QuelleDong, Yuwei. Meta-analysis of the association between adiponectin SNP 45, SNP 276 and type 2 diabetes mellitus. INPLASY - International Platform of Registered Systematic Review Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0013.
Der volle Inhalt der QuelleWang, Xian. Blood DNA methylation and Type 2 Diabetes Mellitus: a protocol for systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review Protocols, April 2020. http://dx.doi.org/10.37766/inplasy2020.4.0136.
Der volle Inhalt der Quelle